Lv1
30 积分 2024-01-17 加入
Eftilagimod alpha (soluble LAG-3 protein) combined with pembrolizumab as second-line therapy for patients with metastatic head and neck squamous cell carcinoma
2个月前
已完结
Nivolumab Plus Relatlimab: First Approval
2个月前
已完结
Cancer immunotherapy: T cells and neutrophils working together to attack cancers
2个月前
已完结
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
2个月前
已完结
Immune checkpoint therapy—current perspectives and future directions
2个月前
已完结
IGSF8 is an innate immune checkpoint and cancer immunotherapy target
2个月前
已完结
Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells
2个月前
已完结
YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD‐L1/VEGFA Axis
7个月前
已完结
Biology and therapeutic targeting of vascular endothelial growth factor A
8个月前
已完结
Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma
10个月前
已完结
皖公网安备34019202002308
